StockNews.AISignal intelligence
Repligen Corporation · NASDAQ · Healthcare
Browse public RGEN signals with their source context and measured market impact. Open any signal for its permanent analysis page.
RGEN has been in a downtrend for over 1400 days. Adhishthana principles suggest continued weakness in RGEN's stock. RGEN's structure indicates ongoing bearish trends until July 2026. Weak Guna Triads signal a lack of bullish momentum. Long-term rallies are unlikely due to absence of Satoguna in triads.
View signal analysisQ4 adjusted EPS was 44 cents. It beat consensus of 41 cents. Revenue reached $167.55M. It aligned nearly with consensus. 2025 guidance projects $685M–710M sales. Growth remains robust. Order momentum exceeded sales by 6%. Stock rose 8.16%.
View signal analysisRGEN reported Q3 adjusted EPS of 43 cents, exceeding consensus. Sales reached $154.87 million, up 10% year-over-year, outperforming expectations. Raised 2024 EPS guidance to $1.50-$1.58, above consensus estimate. Strong growth in CDMO and equipment sales indicates market recovery. Analyst maintains Outperform rating, citing long-term growth potential.
View signal analysisRepligen made an acquisition offer to Maravai LifeSciences valued at $2.2 billion. This move could enhance Repligen's capabilities in vaccine production.
View signal analysis- Repligen appointed Olivier Loeillot as new CEO effective Sep 1, 2024. - Current CEO Tony J. Hunt will transition to executive chair on the same date. - RGEN shares fell 11.9% following the announcement. - Under Hunt's leadership, RGEN saw annual revenue growth of 30% over nine years. - RGEN revenues declining recently due to absence of COVID-related revenues. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Corporate Developments
View signal analysis- Repligen reported Q1 EPS of 28 cents, missing estimates, with revenues down 17.2%. - Base business revenues declined 9.4%, but chromatography franchise saw slight improvement. - Repligen expects revenues of $620-$650 million for 2024, with adjusted EPS of $1.42-$1.49. - Guidance includes adjusted gross margin of 49%-50% and adjusted operating margin of 13%-14%. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis